SESSION 1: NEW INSIGHTS IN THE BIOLOGY AND DIAGNOSIS OF ITP

Chairmen: M. Michel, F. Zaja

The role of platelets in innate and adaptive immunity
J.W. Semple
Predictive markers of treatment response: where do we stand?
E. Lucchini
SESSION 2: GUIDELINES, DEFINITIONS AND REGISTRIES

Chairmen: M.L. Lozano, G. Moulis

The new EHA guidelines: current status
M. Csenar, W. Ghanima
Why registries are useful: advances and gaps
G. Moulis
SESSION 3: ITP TREATMENT – ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES (PART 1)

Chairmen: T.J. González-López, T. Kühne

Inhibiting Syk in ITP
T.J. González-López
How BTK inhibitors may change the therapeutic approach in ITP
N. Cooper
SESSION 3 ITP TREATMENT – ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES (PART 2)

Chairmen: M. Michel, F. Rodeghiero

Anti-CD38 monoclonal antibodies in ITP: current status
W. Ghanima
Targeting BAFF/BAFF-R in ITP
F. Zaja
Bispecific antibodies and CAR-T cells: do they have a place in ITP?
K. Trautman-Grill
Other novel therapeutic approaches (C1 inhibition, FcRn inhibition)
S. Audia
SESSION 4: ITP IN SPECIFIC SITUATIONS

B. Godeau, F. Rodeghiero

What’s new in childhood / AYA ITP?
T. Kühne, A. Schifferli
ITP during pregnancy: lessons from the last 5 years
J.B. Bussel
Pharmacoeconomics of ITP: does cost matter?
B. Godeau
SESSION 5: QUALITY OF LIFE, ARTIFICIAL INTELLIGENCE, SECONDARY ITP

Quality of life in ITP
A. Hart
What AI can bring to ITP
A.B. Provan
Management of secondary ITP: what differs from primary ITP?
M. Mahévas
SESSION 6: ABSTRACT PRESENTATIONS

N. Cooper, D. Provan

OC1. EARLY T-CELL RECEPTOR REPERTOIRE FEATURES PREDICT LONG-TERM OUTCOME IN PAEDIATRIC IMMUNE THROMBOCYTOPAENIA
A, Malik
OC3. DARATUMUMAB CAN LEAD TO LONG-LASTING REMISSIONS IN PATIENTS WITH REFRACTORY IMMUNE THROMBOCYTOPENIA BUT WITH A HIGH INCIDENCE OF SEVERE INFECTIONS
E. Han
OC4. GENERATION OF SYNTHETIC PATIENTS IN IMMUNE THROMBOCYTOPENIA: EXPERIENCE FROM THE ITALIAN GIMEMA ITP0918 (Immune Thrombocytopenia) REGISTRY
G. Marsili
OC6. BCMA(B-Cell Maturation Antigen)-TARGETING T-CELL-ENGAGER THERAPY INDUCES SUSTAINED REMISSION IN IMMUNE THROMBOCYTOPENIA
M.L. Hütter-Krönke
Privacy Policy | Cookie Policy